Evonik Evonik

X
[{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Searchlight Pharma Announces Suvexx\u00ae Launch in Europe, Along with Deal Expansion to all E.U. Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Nuvo Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.

            Lead Product(s): Naproxen Sodium,Sumatriptan

            Therapeutic Area: Neurology Product Name: Suvexx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Orion Corporation

            Deal Size: $0.6 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY